We are live on
!
Find out more
ESPR
Esperion Therapeutics
ESPR
ESPR
Delisted
ESPR was delisted on the 10th of July, 2026.
119 hedge funds and large institutions have $647M invested in Esperion Therapeutics in 2017 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 38 increasing their positions, 31 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
248% more capital invested
Capital invested by funds: $186M → $647M (+$461M)
236% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 11
23% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 31
20% more funds holding
Funds holding: 99 → 119 (+20)
15.49% more ownership
Funds ownership: 65.72% → 81.22% (+15%)
70% less call options, than puts
Call options by funds: $19.7M | Put options by funds: $66.3M
Holders
119
Holders Change
+20
Holders Change %
+20.2%
% of All Funds
2.96%
Holding in Top 10
5
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+400%
% of All Funds
0.12%
New
37
Increased
38
Reduced
31
Closed
11
Calls
$19.7M
Puts
$66.3M
Net Calls
-$46.6M
Net Calls Change
-$48.9M
Top Buyers
| 1 |
BlackRock
New York
|
+$29.3M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$29.2M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$16.1M |
| 4 |
PA
Pinnacle Associates
New York
|
+$15M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.4M |
